Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPOwER: Gene Testing for Endocrine Therapy Response in Breast Cancer
NCT03211572Phase 2
Key facts
- Status
- Unknown
- Start
- Aug 2017
- Primary completion
- Aug 2018
- Sponsor
- Ottawa Hospital Research Institute
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Drugs
- tamoxifenanastrozole
- Conditions
- breast cancer
01
Overview
Phase 2, open-label, single-arm trial of tamoxifen and anastrozole in breast cancer, sponsored by Ottawa Hospital Research Institute. Primary endpoint: Endocrine Therapy response at 1 year. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Endocrine Therapy
Participants receive endocrine therapy for 2 weeks prior to surgery based on menopausal status.
03
Who it enrols
Patients with newly diagnosed operable ER+/HER2- invasive breast cancer (size ≥ 1.5cm) scheduled for surgery in 2-6 weeks.
04
Endpoints
Primary
Endocrine Therapy response
Secondary
Biomarker Predictive value
Beyond the preview
Go deeper on NCT03211572.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03211572.